source
- Beacon Therapeutics reports positive pivotal trial results for X-linked retinitis pigmentosa gene therapyBeacon Therapeutics said its gene therapy for X-linked retinitis pigmentosa (XLRP) met the primary endpoint in a phase 2/3 Vista study. The trial enrolled 85 male patients and compared two dose lev…
- Novartis faces another setback while Novo drops Nordisk partnershipThe latest edition of Endpoints Weekly notes that Novartis experienced another failure, though the newsletter does not provide details about the product or trial. It also reports that Novo Nordisk…